Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05060380
Other study ID # 300004541
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2024
Est. completion date December 1, 2025

Study information

Verified date January 2024
Source University of Alabama at Birmingham
Contact HARSHVARDHAN SINGH, PhD
Phone 2059961413
Email hsingh@uab.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the 6 month randomized controlled trial is to investigate the feasibility of a novel progressive muscle resistance exercise in postmenopausal women with low bone mass.


Description:

In 2008, medical cost of osteoporosis and osteoporosis-related fractures was estimated to be $22 billion. This is further expected to rise because of an increase of 20% in population with osteoporosis, amounting to 12 million adults over the age of 50 years, by 2020, out of which 80% will be postmenopausal women. Unfortunately, benefits due to pharmacological interventions have plateaued. Consequently, there is a critical need to identify complementary therapies to enhance the treatment of low bone mass in older adults. The aim of this study is to examine the feasibility of novel progressive muscle resistance exercise in postmenopausal women with low bone mass. Muscle will be assessed via imaging techniques and isokinetic dynamometer. Physical activity will be assessed via activity monitors. Blood will be collected to assess bone and muscle biomarkers. Balance will be assessed via clinical and biomechanical tests. Testing will be performed at 4 time points: baseline, 1 month, 3 month, and 6 months except imaging which will be done at the baseline and 6 months. The findings from this study will help us to understand the feasibility of resistive muscle exercise program in postmenopausal women with low bone mass.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 44
Est. completion date December 1, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 55 Years to 85 Years
Eligibility Inclusion Criteria: - independent ambulatory - diagnosed with low bone mass Exclusion Criteria: - uncontrolled hypertension - secondary osteoporosis - fragility fracture, - clinical or laboratory evidence of hepatic - renal disease, - uncontrolled disorders of the parathyroid - thyroid glands, - a history of cancer in the past 5 years, - any structured resistance training within the previous year, and - past therapy with any drug for osteoporosis, - any current therapy for osteoporosis except zoledronic acid, - inability to walk independently or - any other medical conditions which could restrict the potential participants from full participation as decided by their physician.

Study Design


Intervention

Other:
Exercise training
Progressive muscle resistive exercise will be performed by the experimental group only. Control group will maintain their normal level of daily activity.

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bone density measured by magnetic resonance imaging (MRI) technique Change in trabecular density assessed using MRI technique. An increase in trabecular density is expected at the end of the study. Baseline
Primary Bone density measured by magnetic resonance imaging (MRI) technique Change in trabecular density assessed using MRI technique. An increase in trabecular density is expected at the end of the study. 6 months
Secondary Muscle strength Change in quadriceps muscle strength assessed using isokinetic dynamometer. An increased quadriceps strength is expected at the end of the study Baseline
Secondary Muscle strength Change in muscle strength assessed using isokinetic dynamometer. An increased quadriceps strength is expected at the end of the study 1 month
Secondary Muscle strength Change in muscle strength assessed using isokinetic dynamometer. An increased quadriceps strength is expected at the end of the study. 3 months
Secondary Muscle strength Change in muscle strength assessed using isokinetic dynamometer. An increased quadriceps strength is expected at the end of the study. 6 months
Secondary Serum bone biomarker: Bone Alkaline Phosphatase (BAP) Change in BAP assessed using assay techniques. An increase in BAP is expected at the end of the study. Baseline
Secondary Serum bone biomarker: Bone Alkaline Phosphatase (BAP) Change in BAP assessed using assay techniques. An increase in BAP is expected at the end of the study. 1 month
Secondary Serum bone biomarker: Bone Alkaline Phosphatase (BAP) Change in BAP assessed using assay techniques. An increase in BAP is expected at the end of the study. 3 months
Secondary Serum bone biomarker: Bone Alkaline Phosphatase (BAP) Change in BAP assessed using assay techniques. An increase in BAP is expected at the end of the study. 6 months
Secondary Physical activity: International Physical Activity Questionnaire (IPAQ) Change in metabolic equivalent (MET)-minute scores assessed using IPAQ questionnaire. An improved MET-minute score is expected at the end of this study. baseline
Secondary Physical activity: International Physical Activity Questionnaire (IPAQ) Change in MET-minute scores assessed using IPAQ questionnaire. An improved MET-minute score is expected at the end of this study. 1 month
Secondary Physical activity: International Physical Activity Questionnaire (IPAQ) Change in MET-minute scores assessed using IPAQ questionnaire. An improved MET-minute score is expected at the end of this study. 3 month
Secondary Physical activity: International Physical Activity Questionnaire (IPAQ) Change in MET-minute scores assessed using IPAQ questionnaire. An improved MET-minute score is expected at the end of this study. 6 months
Secondary Oxygen uptake (VO2) Change in VO2 assessed using metabolic cart. A greater value of VO2 is expected at the end of this study. Baseline
Secondary Oxygen uptake (VO2) Change in VO2 assessed using metabolic cart. A greater value of VO2 is expected at the end of this study. 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06287502 - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis N/A
Completed NCT03822078 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women Phase 1
Recruiting NCT05845021 - Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04736693 - Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Completed NCT02922478 - Role of Comorbidities in Chronic Heart Failure Study
Recruiting NCT02635022 - Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Active, not recruiting NCT02617303 - Prevention of Falls and Its Consequences in Elderly People N/A
Completed NCT02566655 - Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis Phase 1
Completed NCT03420716 - Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women N/A
Not yet recruiting NCT02223572 - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture N/A
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Not yet recruiting NCT01854086 - Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday N/A
Unknown status NCT01913834 - Nasally and sc Administered Teriparatide in Healthy Volunteers Phase 1
Completed NCT02003716 - DeFRA Questionnaire as an Anamnestic Form N/A
Completed NCT01757340 - Calorie Restriction With Leucine Supplementation N/A
Completed NCT01694784 - Understanding and Discouraging Overuse of Potentially Harmful Screening Tests N/A
Completed NCT01401556 - C-STOP Fracture Trial N/A